Ironwood Pharmaceuticals heads into the back half of August with a notable divergence at its core — short sellers are unwinding positions even as the stock trades at a fraction of where analysts think it should be.
The short interest story has shifted materially over the past week. At 10% of free float, the position remains elevated by any measure, but the direction is clearly lower — down 7.4% in the past week alone, with the daily estimate falling from roughly 17.6 million shares borrowed in early August to 16.3 million. That unwind has been steady and methodical, not a single-day cover. The ORTEX short score has tracked the move, slipping from 58.7 to 56.9 over the same period. Borrow conditions tell a permissive story: cost to borrow is running at just 0.51%, and availability stands at over 1,400% — meaning for every share currently lent out, there are fourteen more sitting ready in the lending pool. There is no squeeze dynamic here. New shorts can enter freely, which makes the ongoing cover more deliberate-looking than forced.
Options positioning has rotated sharply toward the bullish side. The put/call ratio has dropped to 0.71, sitting 1.4 standard deviations below its 20-day average of 0.85. That is a meaningful tilt — earlier in July the ratio was running near 0.95, and over the past two weeks it has compressed steadily as call interest has grown relative to puts. Combined with the short unwind, both positioning signals are now pointing in the same direction.
The Street is more cautious than the options market implies, though it has been moving in a constructive direction. Analyst coverage has been thin and the most recent meaningful actions date to early 2026. Citizens upgraded and raised its target to $10 in late February. Wells Fargo lifted its target to $5 in January while keeping an equal-weight rating. With the stock near $4.31, the consensus mean target of $6.10 implies roughly 41% upside — plausible on a valuation basis given an EV/EBITDA of just 3.1x and a PE of roughly 3.0x. EPS momentum factor scores rank in the 79th percentile, and the EV/EBIT metric sits in the 88th percentile for value, suggesting the market is not paying for much beyond current earnings. The one drag on the factor picture is forward EPS growth, which is deeply negative year-on-year — a hangover from post-peak linaclotide dynamics that the bull case needs to answer.
Institutional flows add a layer of interest. BlackRock added more than 4.4 million shares, bringing its stake to 10.8% as of end-July — the largest single reported increase among major holders. State Street also added over 1.4 million shares in the same period. Against that, Sarissa Capital — a long-running activist holder — trimmed its position by 6.7 million shares in the March quarter, a meaningful exit. The insider picture is less encouraging: a broad wave of executive sales hit on February 24, including the CEO at $3.66, and the Chief Accounting Officer sold again in early July at $4.52. None of the values are enormous in absolute terms, but the absence of any buying from management is a gap in the bull narrative.
The most recent earnings print, reported August 6, produced a one-day gain of 4.1% — a clean beat reaction — though the stock gave back 1.7% over the following five days. The next event is not scheduled until November 6. Between now and then, the key variable is whether the short cover continues at pace or stalls out, and whether the call-side options interest reflected in the PCR shift turns into actual upside momentum — or quietly fades as the stock tests resistance near the low end of the analyst target range.
See the live data behind this article on ORTEX.
Open IRWD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
